(MENAFN- EIN Presswire) EINPresswire/ -- What Is The Expected Cagr For The Urea Cycle Disorders Treatment Market Through 2025? In recent times, the market size for treatment of urea cycle disorders ...

OLPRUVA™ preliminary launch activities progressing; building out commercial and medical affairs teams to support U.S. launch in Q2 2023, with drug availability anticipated by early July 2023 Poster ...

Acer Therapeutics reports data from a survey of UCD healthcare providers show taste and odor are the most important attributes when considering treatment options and adherence GENEVA, SWITZERLAND / ...

GENEVA, SWITZERLAND / ACCESSWIRE / May 18, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced ...

Data are based on the largest inpatient cohort with SIAD reported to date. Oral urea effectively treats hyponatremia in patients with the syndrome of inappropriate antidiuresis (SIAD) who fail to ...

A copy of the poster presentation from the 2023 SIMD Meeting is available on Acer’s website at: https://www.acertx.com/wp-content/uploads/2023/03/2023-SIMD-DCE ...